2/27/2022 0 Comments Seqirus spaceplanPlasma products are the key revenue driver for CSL, with the Behring business generating over US$8 billion in revenue.īrokers at Macquarie Group last week upgraded CSL shares to "outperform" from "neutral", lifting their price target to $338 a share after noting that easing disruptions in the key US plasma collection market would help CSL.ĭisclaimer - Hive Empire Pty Ltd (trading as, ABN: 18 118 785 121) provides factual information, general advice and services on financial products as a Corporate Authorised Representative (432664) of Advice Evolution Pty Ltd AFSL 342880. It will have space for 40 Australian companies looking to move early stage research towards commercialisation.Īnalysts also expect a revival for CSL’s major blood products business as centres reopen following the vaccine rollout advancing across the world. The vaccine maker has inked a deal with the University of Melbourne and the Walter and Eliza Hall Institute to launch the $95 million incubator project, with support from the Victorian government’s Breakthrough Victoria Fund. Meanwhile, CSL is also stepping up its investment in research and development, after launching an incubator program at its new Melbourne headquarters that is designed to commercialise Australian ideas and keep research onshore. I agree to the Privacy & Cookies Policy, Terms of Use, Disclaimer & Privacy Policy and to receive emails from Finder Under the terms of its public-private partnership with the US Department of Health and Human Services (HHS), Seqirus can deliver 150 million influenza vaccine doses to the US government to support an influenza pandemic response within 6 months. It was originally approved by the FDA in 2020 in a single dose, pre-filled syringe (PFS) presentation.Īirborne respiratory diseases such as influenza have been a focus of public health systems worldwide since the COVID-19 pandemic spread in March 2020 and the fresh approval is expected to bolster Seqirus’ product line. The biotech giant’s shares have likely lifted on Wednesday after its influenza vaccine business, Seqirus, overnight announced it had received approval from the the US Food and Drug Administration (FDA) for the Audenz vaccine.Īudenz is the first-ever adjuvanted, cell-based influenza vaccine to help protect individuals 6 months and older against influenza A(H5N1) in the event of a pandemic and is available in multi-dose vial (MDV) form. The stock was up more than 1% to $319.78 in early trading. Shares in CSL ( ASX: CSL) are among the list of most traded stocks on the ASX on Wednesday, building on the recent momentum that has seen the already expensive stock gain over 7% in the past month. Shares in biotech giant CSL are up 7% in the past month alone. ![]() #Seqirus spaceplan driver#
0 Comments
Leave a Reply. |
AuthorMike ArchivesCategories |